CN101181249A - 姜黄素在制备尿酸转运子urat1抑制药物中的应用 - Google Patents
姜黄素在制备尿酸转运子urat1抑制药物中的应用 Download PDFInfo
- Publication number
- CN101181249A CN101181249A CNA2007101901359A CN200710190135A CN101181249A CN 101181249 A CN101181249 A CN 101181249A CN A2007101901359 A CNA2007101901359 A CN A2007101901359A CN 200710190135 A CN200710190135 A CN 200710190135A CN 101181249 A CN101181249 A CN 101181249A
- Authority
- CN
- China
- Prior art keywords
- curcumin
- uric acid
- urat1
- acid transporter
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 28
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 229940116269 uric acid Drugs 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000000452 restraining effect Effects 0.000 title claims description 10
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 title abstract description 26
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 title description 21
- 235000003392 Curcuma domestica Nutrition 0.000 title 1
- 244000008991 Curcuma longa Species 0.000 title 1
- 235000003373 curcuma longa Nutrition 0.000 title 1
- 235000013976 turmeric Nutrition 0.000 title 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 100
- 229940109262 curcumin Drugs 0.000 claims abstract description 50
- 235000012754 curcumin Nutrition 0.000 claims abstract description 50
- 239000004148 curcumin Substances 0.000 claims abstract description 50
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 50
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 229930003935 flavonoid Natural products 0.000 claims abstract description 6
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 6
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 4
- 239000002775 capsule Substances 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 2
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000000178 monomer Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108010078530 urate transporter Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229950000193 oteracil Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 206010021131 Hypouricaemia Diseases 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 108091006745 SLC22A12 Proteins 0.000 description 1
- 101150078067 SLC22A12 gene Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及黄酮类单体化合物姜黄素的新用途，具体是涉及姜黄素在制备尿酸转运子URAT1抑制药物中的应用。经动物试验结果表明：姜黄素对高尿酸血模型动物表达异常增高的尿酸转运子URAT1具有确切的抑制作用，而对正常动物的正常水平的尿酸转运子URAT1表达无显著抑制作用，具有很好的安全性，利用姜黄素配以相关的药用辅料，用常规的制剂方法可制成姜黄素口服液、胶囊剂、片剂、颗粒剂等尿酸转运子URAT1的抑制药物，可用于治疗与尿酸转运子URAT1异常高表达相关的疾病。
Description
技术领域：本发明涉及黄酮类单体化合物姜黄素的新用途，具体是涉及姜黄素在制备尿酸转运子URAT1抑制药物中的应用。
背景技术：尿酸排出减少或生成增加，可导致血液中尿酸浓度增高，直接或间接引起相关疾病。尿酸的排泄是一复杂过程，尿酸随血液循环流入肾小球时，游离型的尿酸将全部滤过；在近端肾小管有约99％尿酸盐被重吸收(Diamond HS，Meisel AD.Postsecretory reabsorption of urate in man.Arthritis AndRheumatism，1975，18(6)：805-809.)。位于近曲小管的尿酸转运子(蛋白)URAT1参与尿酸重吸收过程，通过与阴离子的交换将尿酸盐由管腔转运入细胞。URAT1蛋白主要分布于肾皮质近曲小管上皮细胞向腔膜，是一个电中性的尿酸转运蛋白。URAT1基因由Enomoto等于2002年首先从人肾脏克隆出来，位于染色体11q13，由SLC22A12基因编码，由10个内含子9个外显子组成，拥有12个跨膜结构域，其cDNA全长2642bp，编码区1659bp，编码含555个氨基酸的蛋白质。原发性肾低尿酸血症(hypouricemia)病人的SLC22A12基因缺陷病例进一步证明人的URAT1(hURAT1)参与尿酸的重吸收(Atsushi Enomoto，Hiroaki Kimura，Arthit Chairoungdua，Yasuhiro Shigeta，et al.Molecular identificationof a renal urate-anion exchanger that regulates blood urate levels.Nature，2002，417(6887)：447-452)。
姜黄素结构式、分子式和美国化学文摘收录号(CAS No.)见下：
姜黄素可以由天然产物中分离得到，例如有文献报道了采用渗漉法提取及大孔树脂分离正交试验，确定了提取姜黄素用9倍体积的70％乙醇，以3mL/min的速度渗漉的最佳提取工艺和利用D101大孔树脂纯化姜黄素工序中调节上样料液以及pH7，80％乙醇以4ml/min的速率洗脱的最佳分离工艺，由姜黄中分离姜黄素(尤本明，王忠壮，胡晋红.姜黄中姜黄素的提取及分离工艺研究.药学服务与研究2006；6(4)：277-279)。也有报道由化学改构/合成得到姜黄素(Venkateswarlu，Somepalli；Ramachandra，Marellapudi S.；Subbaraju，Gottumukkala V.Synthesis and biological evaluation ofpolyhydroxycurcuminoids.Bioorganic & Medicinal Chemistry(2005)，13(23)，6374-6380.)。
姜黄素已见有多种生理和药理活性的报道，包括抗氧化作用、抗肿瘤作用、抗炎作用、抗病毒作用等(许东晖，王胜，金晶，梅雪婷，许实波.姜黄素的药理作用研究进展.中草药2005；36(11)：1737-1740)。但单体化合物姜黄素用于制备针对尿酸转运子URAT1的抑制药物，则未见报道。
发明内容：
本发明的目的是提供黄酮类单体化合物姜黄素的新用途，具体是姜黄素在制备尿酸转运子URAT1抑制药物中的应用。
本发明的技术解决方案之一是：提供黄酮类单体化合物姜黄素在制备尿酸转运子URAT1抑制药物的新用途。该新用途包括了以本发明所述的姜黄素，配以本领域的技术人员所熟知的药用辅料(赋形剂、助溶剂、控释剂等)，制成本领域的技术人员所熟知的剂型(包括口服液、注射剂、胶囊剂、片剂、颗粒剂、微囊剂等)，用于制备尿酸转运子URAT1抑制药物。
本发明的优点是，提供了对尿酸转运子URAT1具有确切抑制调节作用的姜黄素，用于制备尿酸转运子URAT1抑制药物，可用于治疗与尿酸转运子URAT1异常高表达相关疾病。与针对痛风或者高尿酸血病症的发明比较，本发明提供的单体化合物姜黄素制备尿酸转运子URAT1抑制药物新用途具有3个明显的进步和优点：1、有效成分确切(单体化合物)；2、作用靶点明确(尿酸排泄过程中重吸收作用的尿酸转运子URAT1)；3、调节作用明确(抑制调节)。
本发明利用高尿酸血动物模型在基因转录水平和蛋白表达水平上科学地评价并确定了单体化合物姜黄素对尿酸转运子URAT1的抑制调控作用。
本发明所涉及的单体化合物姜黄素对模型动物表达异常增高的尿酸转运子URAT1具有确切的抑制作用；而对正常动物的正常水平的尿酸转运子表达无显著抑制作用，具有很好的安全性。
为了更好的理解本发明的实质，下面将用单体化合物姜黄素的的药理实验及结果来说明其在制备尿酸转运子URAT1抑制药物中的应用。
具体实施方式：以下实施例仅作为进一步阐述发明之用，不能用来限制本发明。
实施例1：黄酮类单体化合物姜黄素对尿酸转运子URAT1的抑制调节作用
实验动物：昆明种小鼠，15-20克，雄性
药物配制：姜黄素均匀分散于生理盐水中，用于灌胃给药，给药剂量为25mg/kg
实验材料：Trizol Reagment(Invigen)，氯仿，异丙醇，无水乙醇，DEPC，M-MLV反转录酶，PCR试剂盒，RIPA裂解液等
实验仪器：高速冷冻离心机，高速匀浆机，Bio-rad垂直电泳槽，MBI-PCR仪、水平电泳槽等
实验模型：小鼠高尿酸血症模型。
实验方法：
1、模型的建立：动物适应环境1周后，灌胃给予氧嗪酸钾盐250mg/kg；对照给予等体积生理盐水，造模周期10天。
2、给药：造模期间同时给药，在给予氧嗪酸钾盐造模/生理盐水对照1h后，灌胃给予单体化合物姜黄素25mg/kg；对照给予生理盐水。
3、小鼠处死及组织的保存：小鼠于灌胃给予姜黄素/生理盐水后1小时处死，冰台上分离肾脏组织，肾组织经液氮冷冻后保存于-80℃。
4、蛋白质印迹法(Western-blotting)：取组织约100mg加入1ml的RIPA裂解液匀浆提取，12000g 4℃离心15分钟，得肾脏组织总蛋白提取液，Bradford法测蛋白浓度，稀释蛋白样品至终浓度为5ug/ul。混合上样缓冲液变性上样，SDS-PAGE凝胶电泳后PVDF转膜，封闭液封闭1小时后加入mURAT1抗体(根据NCBI数据库mURAT1蛋白序列制备，使用浓度1∶4000)4℃孵育过夜，二抗(1∶4000)室温摇床孵育1小时，HRP-ECL发光，暗室曝光显影。胶片扫描后对图片进行灰度分析。
5、逆转录聚合酶链反应(RT-PCR)：提取小鼠肾脏总RNA，逆转录得到cDNA模板，根据NCBI数据库的mURAT1基因设计引物，进行mURAT1目的基因扩增。扩增产物经琼脂糖凝胶电泳后UV成像，对图片进行灰度分析。
实验结果：
a.蛋白质印迹法Western-Blotting
| Groupn＝5 | 空白+生理盐水 | 空白+姜黄素 | 模型+生理盐水 | 模型+姜黄素 |
| 灰度值 | 44.9±14.2 | 41.2±13.3 | 84.3±18.7++ | 51.7±12.5** |
++P＜0.01与空白+生理盐水组比较 **P＜0.01与模型+生理盐水组比较连续10天灌胃给予氧嗪酸钾盐250mg/kg造模造成小鼠肾组织中URAT1蛋白高水平表达，灰度值达到84.3，显著高于空白对照44.9。灌胃给予25mg/kg的单体化合物姜黄素可显著抑制模型小鼠肾组织中URAT1蛋白的高水平表达，灰度值为51.7，接近空白对照水平。说明单体化合物姜黄素显著抑制模型动物异常增高的尿酸转运子URAT1蛋白表达。灌胃给予单体化合物姜黄素对空白小鼠肾组织中URAT1蛋白表达水平无显著影响，说明单体化合物姜黄素对小鼠肾组织正常水平的URAT1蛋白无显著抑制作用，具有较好的安全性。
b.逆转录聚合酶链反应RT-PCR
| Groupn＝5 | 空白+生理盐水 | 空白+姜黄素 | 模型+生理盐水 | 模型+姜黄素 |
| 灰度值 | 33.0±9.1 | 35.7±10.2 | 68.7±18.0++ | 38.9±10.4** |
++P＜0.01与空白+生理盐水组比较 **P＜0.01 与模型+生理盐水组比较连续10天灌胃给予氧嗪酸钾盐250mg/kg造模造成小鼠肾组织中URAT1 mRNA高水平表达，灰度值达到68.7，显著高于空白对照33.0。灌胃给予25mg/kg的单体化合物姜黄素可显著抑制模型小鼠肾组织中URAT1 mRNA的高水平表达，灰度值为38.9，接近空白对照水平。说明单体化合物姜黄素可在转录水平上抑制异常增高的尿酸转运子URAT1 mRNA表达。灌胃给予单体化合物姜黄素的空白小鼠肾组织中URAT1 mRNA表达水平为35.7，相对于空白对照组无显著变化，说明单体化合物姜黄素对小鼠肾组织正常水平的URAT1 mRNA无显著抑制作用，具有较好的安全性。
实施例2：
将单体化合物姜黄素按照常规制剂方法，加入水及适量增溶剂(聚乙二醇400)溶解，分装，灭菌，制备成规格为20mg/ml的姜黄素口服液；
将单体化合物姜黄素按照常规制剂方法，软胶囊材质选用明胶和山梨醇，制备成规格为20mg/粒的姜黄素胶囊；
将单体化合物姜黄素按照常规制剂方法，加入赋形剂环糊精，混合均匀，制粒，压片，制备成规格为20mg/片的姜黄素片剂。
Claims (1)
1.黄酮类单体化合物姜黄素在制备尿酸转运子URAT1抑制药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007101901359A CN100571692C (zh) | 2007-11-15 | 2007-11-15 | 姜黄素在制备尿酸转运子urat1抑制药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007101901359A CN100571692C (zh) | 2007-11-15 | 2007-11-15 | 姜黄素在制备尿酸转运子urat1抑制药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101181249A true CN101181249A (zh) | 2008-05-21 |
| CN100571692C CN100571692C (zh) | 2009-12-23 |
Family
ID=39446764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007101901359A Expired - Fee Related CN100571692C (zh) | 2007-11-15 | 2007-11-15 | 姜黄素在制备尿酸转运子urat1抑制药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100571692C (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100015260A1 (en) * | 2008-07-21 | 2010-01-21 | Kailash Chandra Agarwal | Development of biochemically standardized extracts from fresh rhizomes of turmeric (curcuma longa) for treatment of diseases caused by hyperuricemia |
| CN108653539A (zh) * | 2018-07-19 | 2018-10-16 | 东莞市广易中医药发展有限公司 | 一种降低尿酸药食同源压片及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100488498C (zh) * | 2006-12-29 | 2009-05-20 | 神威药业有限公司 | 姜黄提取物在制备预防及延缓慢性肾功能衰竭药物中的应用 |
-
2007
- 2007-11-15 CN CNB2007101901359A patent/CN100571692C/zh not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100015260A1 (en) * | 2008-07-21 | 2010-01-21 | Kailash Chandra Agarwal | Development of biochemically standardized extracts from fresh rhizomes of turmeric (curcuma longa) for treatment of diseases caused by hyperuricemia |
| US8808768B2 (en) * | 2008-07-21 | 2014-08-19 | Kailash Chandra Agarwal | Development of biochemically standardized extracts from fresh rhizomes of turmeric (Curcuma longa) for treatment of diseases caused by hyperuricemia |
| CN108653539A (zh) * | 2018-07-19 | 2018-10-16 | 东莞市广易中医药发展有限公司 | 一种降低尿酸药食同源压片及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100571692C (zh) | 2009-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Rhodiola crenulata attenuates apoptosis and mitochondrial energy metabolism disorder in rats with hypobaric hypoxia-induced brain injury by regulating the HIF-1α/microRNA 210/ISCU1/2 (COX10) signaling pathway | |
| CN101181345B (zh) | 槐米黄酮提取物在制备尿酸转运子urat1抑制药物中的应用 | |
| AU2014360040B2 (en) | Desmodium styracifolium (Osb.) Merr. flavonoids capsule, method of preparing same, and application thereof | |
| CN104922176B (zh) | 一种野菊花提取物的应用 | |
| CN1919856A (zh) | 络石藤总木脂素提取物,提取方法及该提取物和其中有效成分的医药用途 | |
| WO2019041467A1 (zh) | 毛蕊花糖苷在制备预防或治疗肾小球足细胞损伤型肾脏疾病的药物中的用途 | |
| CN101181261A (zh) | 杨梅素在制备尿酸转运子urat1抑制药物中的应用 | |
| CN1723955A (zh) | 射干提取物及其制备方法和用途 | |
| CN101181287A (zh) | 葛根素在制备尿酸转运子urat1抑制药物中的应用 | |
| CN100571692C (zh) | 姜黄素在制备尿酸转运子urat1抑制药物中的应用 | |
| CN108434130A (zh) | 氯硝柳胺乙醇胺盐及其药物组合物的应用 | |
| CN1817898A (zh) | 白薇总皂苷及其皂苷化合物在抗炎药物中的应用 | |
| CN103446166B (zh) | 肝功能改善剂 | |
| Shui et al. | Jieduquyuziyin prescription suppresses IL-17 production and Th17 activity in MRL/lpr mice by inhibiting expression of Ca 2+/calmodulin-dependent protein kinase-4 | |
| CN101181262A (zh) | 香豆素单体化合物在制备尿酸转运子urat1抑制药物中的应用 | |
| CN101265177A (zh) | 洋芫荽子酸类化合物 | |
| CN114748518B (zh) | 含有咖啡酸酯和灯盏花素的抗肠癌的口服制剂及其制备方法 | |
| CN105560302B (zh) | 老鹳草水提物在制备抗血管生成类药物中的应用 | |
| CN104208089B (zh) | 一种用于治疗家禽腺胃炎的胃漂浮制剂及其制备方法 | |
| CN108261435A (zh) | 一种诸葛菜生物碱类提取物及其在制备保肝制品中的应用 | |
| CN102153630A (zh) | 一种环八肽及其制备方法和在制药中的应用 | |
| JP7022064B2 (ja) | 薬用のアンブローシア属植物抽出物 | |
| CN101530417A (zh) | 桑皮苷在预防或治疗高尿酸血症和痛风中的应用 | |
| CN109394798B (zh) | 一种桂东黄菌干提取物的制备方法及其降尿酸应用 | |
| EP3053575B1 (en) | Agent for preventing or ameliorating renal dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091223 |